Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer

Next Previous
Search
Trial Profile

A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Piflufolastat F18 (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Diagnostic use; Registrational
  • Acronyms CONDOR
  • Sponsors Progenics Pharmaceuticals

    • Most Recent Events

    • 22 Feb 2024 According to a Curium Pharma media release, based on results from the Phase III PYTHON, OSPREY and CONDOR trial, the imaging AG on 31 January 2024 has submitted marketing authorization application for PYLCLARI (INN: Piflufolastat (18F) formerly known as (18F)-DCFPyL) to the Swiss Agency for Therapeutic Products (Swissmedic) which has been accepted for evaluation.
    • 01 May 2023 According to a Curium Pharma media release, based on data from the Phase III PYTHON, OSPREY and CONDOR trial, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended to grant a marketing authorization for PYLCLARI (piflufolastat (18F)) indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer.
    • 14 Jun 2021 Results presented in a Lantheus Holdings media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top